MarketCap
Facebook
X
TelegramAnnual report 2025
added 03-30-2026
Lantern Pharma Market Cap 2011-2026 | LTRN
As of April 30, 2026 Lantern Pharma has a market cap of $ 22.2 M
Capitalization is the market value of a company whose shares are traded on the stock exchange. It is calculated by multiplying the market price of a share by the total number of the company's shares. Capitalization indicates volatility, risk, and growth potential. This metric is often used for a quick assessment of a company’s investment profile.[1]
Capitalization is an important indicator for investors and analysts, as it helps determine the size and significance of a company in the stock market. Companies with large capitalization are considered more stable and reliable, as they have more resources and financial power to grow and survive in the market.
This metric can be divided into several categories: small (from 300 million to 2 billion dollars), medium (from 2 to 10 billion dollars), and large (over 10 billion dollars). Companies with different levels of capitalization have their own characteristics and risks, so investors usually take this indicator into account when making investment decisions.
Capitalization can also change over time depending on the share price and the number of shares in circulation. Therefore, it is a dynamic indicator that requires constant monitoring and analysis to make well-informed investment decisions.
Annual Market Cap Lantern Pharma
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 13.5 M | 13.3 M | 108 M | 50.7 M | 67.2 M | 93.5 M | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 108 M | 13.3 M | 57.7 M |
References
- Pavone, P. (2019). Market capitalization and financial variables: Evidence from Italian listed companies. International Journal of Academic Research Business and Social Sciences, 9(3), 1356-1371.
Market Cap of other stocks in the Biotechnology industry
| Issuer | Market Cap | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
MorphoSys AG
MOR
|
315 M | - | 2.43 % | $ 254 M |  Germany |
 |
I-Mab
IMAB
|
127 M | - | - | $ 866 M |  China |
 |
Midatech Pharma plc
MTP
|
79 M | - | -18.52 % | $ 27.3 M |  Britain |
 |
Alexion Pharmaceuticals, Inc.
ALXN
|
33.6 B | - | - | $ 40.3 B |  USA |
 |
Aptorum Group Limited
APM
|
6.69 M | $ 0.89 | - | $ 6.54 M | China |
 |
Biophytis SA
BPTS
|
549 M | - | -13.47 % | $ 169 M |  France |
 |
Genfit SA
GNFT
|
168 B | - | 2.54 % | $ 160 B | France |
 |
ACADIA Pharmaceuticals
ACAD
|
3.19 B | $ 22.35 | 0.68 % | $ 3.7 B | USA |
 |
EyeGate Pharmaceuticals, Inc.
EYEG
|
28.9 M | - | -1.52 % | $ 24.7 M | USA |
 |
Applied Molecular Transport
AMTI
|
22.1 M | - | - | $ 10.1 M | USA |
 |
Advaxis
ADXS
|
1.87 M | - | -9.65 % | $ 45.9 M | USA |
 |
Институт стволовых клеток человека
ISKJ
|
2.83 B | - | - | - |  Russia |
 |
Aeterna Zentaris
AEZS
|
41.4 M | - | 5.93 % | $ 314 M |  Canada |
 |
AgeX Therapeutics
AGE
|
14.1 K | - | -10.17 % | $ 12.2 K | USA |
 |
BioNTech SE
BNTX
|
62.9 B | $ 103.69 | 2.08 % | $ 27.2 B | Germany |
 |
Brainstorm Cell Therapeutics
BCLI
|
6.33 M | - | -2.5 % | $ 5.88 M | USA |
 |
Aeglea BioTherapeutics
AGLE
|
724 M | - | - | $ 1.01 B | USA |
 |
Applied Genetic Technologies Corporation
AGTC
|
32.8 M | - | - | $ 26.5 M | USA |
 |
AIkido Pharma
AIKI
|
19.6 M | - | 1.93 % | $ 17.4 M | USA |
 |
Akero Therapeutics
AKRO
|
3.25 B | - | - | $ 3.67 B | USA |
 |
Innate Pharma S.A.
IPHA
|
363 M | $ 1.48 | -0.67 % | $ 235 M | France |
 |
Akouos
AKUS
|
172 M | - | 0.23 % | $ 488 M | USA |
 |
Allakos
ALLK
|
114 M | - | - | $ 28.6 M | USA |
 |
AlloVir
ALVR
|
13.1 M | - | 4.14 % | $ 49.1 M | USA |
 |
Can-Fite BioPharma Ltd.
CANF
|
4.81 M | $ 3.65 | 22.48 % | $ 6.01 M |  Israel |
 |
Ampio Pharmaceuticals
AMPE
|
664 K | - | -11.43 % | $ 502 K | USA |
 |
CureVac N.V.
CVAC
|
3.53 B | - | - | $ 867 M | Germany |
 |
Applied Therapeutics
APLT
|
541 M | - | - | $ 8.42 M | USA |
 |
Aptose Biosciences
APTO
|
2.32 M | - | -45.71 % | $ 1.2 M | Canada |
 |
Aquestive Therapeutics
AQST
|
467 M | $ 4.08 | 0.74 % | $ 436 M | USA |
 |
Aptinyx
APTX
|
9.48 M | - | -39.0 % | $ 4.57 M | USA |
 |
Aravive
ARAV
|
60.4 M | - | -13.39 % | $ 1.45 M | USA |
 |
Aridis Pharmaceuticals
ARDS
|
4.13 M | - | 17.91 % | $ 11.1 M | USA |
 |
Arcutis Biotherapeutics
ARQT
|
3.44 B | $ 22.65 | 1.25 % | $ 2.88 B | USA |
 |
Edesa Biotech
EDSA
|
6.08 M | $ 16.23 | 2.08 % | $ 51.9 M | USA |
 |
Allena Pharmaceuticals
ALNA
|
71.4 M | - | 3.16 % | $ 1.9 M | USA |
 |
Athira Pharma
ATHA
|
1.62 M | - | - | $ 269 M | USA |
 |
Alpine Immune Sciences
ALPN
|
269 M | - | - | $ 2.17 B | USA |
 |
Avenue Therapeutics
ATXI
|
544 K | - | -52.27 % | $ 4.45 M | USA |
 |
Aileron Therapeutics
ALRN
|
38.2 M | - | 10.36 % | $ 9.8 M | USA |
 |
Autolus Therapeutics plc
AUTL
|
322 M | $ 1.42 | 0.71 % | $ 378 M | Britain |
 |
AVROBIO
AVRO
|
56.3 M | - | 1083.1 % | $ 745 M | USA |
 |
Ayala Pharmaceuticals
AYLA
|
7.72 M | - | - | $ 7.46 M | Israel |
 |
AstraZeneca PLC
AZN
|
81.2 B | - | - | $ 96.9 B | Britain |
 |
Evogene Ltd.
EVGN
|
66.3 M | $ 0.79 | 4.79 % | $ 27.9 M | Israel |
 |
Atreca
BCEL
|
49 M | - | -11.76 % | $ 5.79 M | USA |
 |
BioDelivery Sciences International
BDSI
|
308 M | - | -4.8 % | $ 255 M | USA |
 |
Exelixis
EXEL
|
11.7 B | $ 45.0 | 0.69 % | $ 12.2 B | USA |
 |
BeiGene, Ltd.
BGNE
|
253 B | - | 0.49 % | $ 251 B |  Cayman-islands |
 |
Завод ДИОД
DIOD
|
661 M | - | - | - | Russia |